GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marinomed Biotech AG (STU:93Z) » Definitions » Inventory Turnover

Marinomed Biotech AG (STU:93Z) Inventory Turnover : 0.72 (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Marinomed Biotech AG Inventory Turnover?

Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories. Marinomed Biotech AG's Cost of Goods Sold for the three months ended in Mar. 2024 was €0.74 Mil. Marinomed Biotech AG's Average Total Inventories for the quarter that ended in Mar. 2024 was €1.04 Mil. Marinomed Biotech AG's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.72.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Marinomed Biotech AG's Days Inventory for the three months ended in Mar. 2024 was 127.11.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Marinomed Biotech AG's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 1.40.


Marinomed Biotech AG Inventory Turnover Historical Data

The historical data trend for Marinomed Biotech AG's Inventory Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marinomed Biotech AG Inventory Turnover Chart

Marinomed Biotech AG Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventory Turnover
Get a 7-Day Free Trial Premium Member Only 62.21 17.12 10.44 7.05 6.25

Marinomed Biotech AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Inventory Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.01 1.15 1.45 1.76 0.72

Marinomed Biotech AG Inventory Turnover Calculation

Marinomed Biotech AG's Inventory Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Inventory Turnover (A: Dec. 2023 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (A: Dec. 2023 ) / ((Total Inventories (A: Dec. 2022 ) + Total Inventories (A: Dec. 2023 )) / count )
=8.041 / ((1.562 + 1.013) / 2 )
=8.041 / 1.2875
=6.25

Marinomed Biotech AG's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover (Q: Mar. 2024 )
=Cost of Goods Sold / Average Total Inventories
=Cost of Goods Sold (Q: Mar. 2024 ) / ((Total Inventories (Q: Dec. 2023 ) + Total Inventories (Q: Mar. 2024 )) / count )
=0.743 / ((1.013 + 1.057) / 2 )
=0.743 / 1.035
=0.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Marinomed Biotech AG  (STU:93Z) Inventory Turnover Explanation

Inventory Turnover measures how fast the company turns over its inventory within a year. A higher Inventory Turnover means the company has light inventory. Therefore the company spends less money on storage, write downs, and obsolete inventory. If the inventory is too light, it may affect sales because the company may not have enough to meet demand.

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Marinomed Biotech AG's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory =Average Total Inventories (Q: Mar. 2024 )/Cost of Goods Sold (Q: Mar. 2024 )*Days in Period
=1.035/0.743*365 / 4
=127.11

2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Marinomed Biotech AG's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=1.035 / 0.738
=1.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Usually retailers pile up their inventories at holiday seasons to meet the stronger demand. Therefore, the inventory of a particular quarter of a year should not be used to calculate Inventory Turnover. An average inventory is a better indication.


Marinomed Biotech AG Inventory Turnover Related Terms

Thank you for viewing the detailed overview of Marinomed Biotech AG's Inventory Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Marinomed Biotech AG Business Description

Traded in Other Exchanges
Address
Hovengasse 25, Korneuburg, AUT, 2100
Marinomed Biotech AG is a biopharmaceutical company focusing on the development of products in the field of respiratory and ophthalmological diseases. The products marketed by the company are based on its platform Carragelose and Marinosolv. The company develops products for cough, cold, influenza, allergic rhinitis, and ophthalmic diseases. Its product offerings include virus-blocking nasal sprays, virus-blocking decongestant nasal sprays, virus-blocking lozenges, and virus-blocking throat sprays. The company has two reportable segments which are Virology, Immunology, and other, the majority of revenue generated from the virology segment.

Marinomed Biotech AG Headlines

No Headlines